J Gynecol Oncol.  2010 Mar;21(1):3-11. 10.3802/jgo.2010.21.1.3.

Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies

• Burger RA

• KMID: 2173501
• DOI: http://doi.org/10.3802/jgo.2010.21.1.3

Abstract

This article reviews the history and current status of vascular endothelial growth factor targeted therapy for the most common gynecologic malignancies - epithelial ovarian, endometrial and cervical cancers. The biologic rationale for targeting vascular endothelial growth factor (VEGF) for these disease sites is well-founded, and pre-clinical studies have supported the development of anti-VEGF agents. Their classification, known mechanisms of action, unique toxicities and clinical development are herein explored, the latter including issues related to study design, disease site and disease setting.

Keyword

Vascular endothelial growth factor; Ovarian neoplasms; Endometrial neoplasms; Cervical neoplasms; Angiogenesis; Bevacizumab

MeSH Terms

Antibodies, Monoclonal, Humanized
Bevacizumab
Endometrial Neoplasms
Female
Ovarian Neoplasms
Uterine Cervical Neoplasms
Vascular Endothelial Growth Factor A
Antibodies, Monoclonal, Humanized
Vascular Endothelial Growth Factor A